

Drugs@FDA: FDA Approved Drug Products

f [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDE R/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=050790\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=050790)

t [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=050790\)](https://twitter.com/intent/tweet?text=Drugs@FDA: FDA Approved Drug Products&url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=050790)

+

e [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTPS://WWW.ACCESSDATA.FD A.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=050790\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=050790)

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 050790

Company: ALLERGAN

e [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA. GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=050790\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process%26varapplno=050790)

Products on NDA 050790



CSVExcelPrint

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code
RESTASIS MULTIDOSE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	Yes	None
RESTASIS	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	Yes	None

Showing 1 to 2 of 2 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 050790



Original Approvals or Tentative Approvals

CSVExcelPrint

MYLAN - EXHIBIT 1064

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, R
12/23/2002	ORIG-1	Approval	Type 3 - New Dosage Form	PRIORITY	Label (PDF) (https://www.acce) Letter (PDF) (https://www.acce) Review (https://www.accessda)

Showing 1 to 1 of 1 entries

Supplements**CSVExcelPrint**

Action Date	Submission	Submission Classification	Letters, Reviews, L Patient Package I
10/27/2016	SUPPL-25	Labeling- Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/lab)
10/27/2016	SUPPL-24	Manufacturing (CMC)	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/lab)
01/16/2014	SUPPL-22	Manufacturing (CMC)	
12/05/2013	SUPPL-23	Manufacturing (CMC)	
05/31/2013	SUPPL-21	Manufacturing (CMC)	Label (PDF) (https://www.accessdata.fda.gov/drugsatf)
01/16/2013	SUPPL-19	Manufacturing (CMC)	
12/03/2012	SUPPL-20	Labeling- Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/ap)

Action Date	Submission	Submission Classification	Letters, Reviews, L Patient Package I
12/27/2007	SUPPL-13	Labeling- Container/Carton Labels	
10/01/2003	SUPPL-4	Labeling	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/ap
10/01/2003	SUPPL-3	Manufacturing (CMC) -Packaging	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/ap
09/16/2003	SUPPL-1	Labeling	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/lab Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/ap
09/12/2003	SUPPL-2	Manufacturing (CMC)	Review (https://www.accessdata.fda.gov/drugsatfda_docs/nd

Showing 1 to 12 of 12 entries

Labels for NDA 050790

